Patient Reported Outcomes and Patient Voice Among Patients Diagnosed With Low Risk Myelodysplastic Syndrome (LR-MDS) or Unexplained Anemia In Japan
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
56actual
Sites
1
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-13 | actual | When the study began enrolling |
| Primary completion | 2026-02-24 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-02-24 | actual | The whole study's end, after follow-up |
| First posted | 2025-06-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Myelodysplastic Syndrome (MDS)
Interventions
- Other: Health-related quality of life questionnaires
- Other: Qualitative interviews
Primary outcomes
what the primary-completion date above is the date OFParticipant quality of life as assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ C30) patient reported outcome questionnaire
measured Day 1
Participant anemia symptoms as assessed by the Functional Assessment of Cancer Therapy - Anemia (FACT-An) patient reported outcome questionnaire
measured Day 1
Symptom severity as assessed by the Patient Global Impression-Severity (PGI-S) patient reported outcome questionnaire
measured Day 1
General health status of participants as assessed by the EQ-5D-5L patient reported outcome questionnaire
measured Day 1
Participant baseline socio-demographics
measured Baseline
Participant baseline clinical characteristics
measured Baseline
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed